Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Publication: [Philadelphia, PA] : Taylor & Francis
Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989-

Antibodies, Monoclonal, Murine-Derived/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Boronic Acids/*administration & dosage ; Cisplatin/*administration & dosage ; Dexamethasone/*administration & dosage ; Etoposide/*administration & dosage ; Ifosfamide/*administration & dosage ; Immunotherapy/*methods ; Lymphoma, Large B-Cell, Diffuse/*drug therapy ; Pyrazines/*administration & dosage; Adult ; Aged ; Bortezomib ; Combined Modality Therapy/methods ; Disease-Free Survival ; Humans ; Middle Aged ; Proteasome Endopeptidase Complex/metabolism ; Recurrence ; Rituximab ; Time Factors ; Treatment Outcome

Patients with relapsed or refractory diffuse large B-cell lymphoma may experience extended survival with second-line chemotherapy and autologous stem cell transplant (ASCT). Since a major determinant of outcome after ASCT is responsiveness to second-line therapy, the development of more effective second-line treatments is desirable. We investigated the addition of bortezomib to rituximab, dexamethasone, ifosfamide, cisplatin and etoposide (VIPER). Fifteen patients were enrolled, of whom seven were refractory to first-line chemotherapy and only three had maintained first response for 1 year. Nine (60%) patients achieved objective responses, of which three (20%) were IWC-PET (International Workshop Criteria positron emission tomography) complete responses. Median progression-free survival was 3 months, and median overall survival was 10 months. At a median follow-up of 26 months, five patients (33%) remained alive. Treatment was well tolerated with no unexpected toxicity. Although response rates did not meet predefined criteria, activity was at least comparable to other second-line approaches despite a poor-prognosis patient population.

0 (Antibodies, Monoclonal, Murine-Derived)
0 (Boronic Acids)
0 (Pyrazines)
4F4X42SYQ6 (Rituximab)
69G8BD63PP (Bortezomib)
6PLQ3CP4P3 (Etoposide)
7S5I7G3JQL (Dexamethasone)
EC 3.4.25.1 (Proteasome Endopeptidase Complex)
Q20Q21Q62J (Cisplatin)
UM20QQM95Y (Ifosfamide)

Date Created: 20120124 Date Completed: 20121210 Latest Revision: 20190116

20231215

10.3109/10428194.2012.656629

22263572